Pulmonx Q2 revenue falls 5% to $22.8 million; net loss narrows to $10.1 million
Pulmonx reported second-quarter 2026 revenue of $22.8 million, down 5% from a year earlier, as international sales fell because of a lack of sales into China while its registration certificate was awaited. Net loss narrowed to $10.1 million, or $0.24 per share, from $15.2 million, or $0.38 per share, as operating expenses fell 16%. The company kept its full-year 2026 revenue outlook of $90 million to $92 million.
Key points
- Q2 2026 worldwide revenue was $22.8 million, down 5% from $23.9 million; U.S. revenue was $14.2 million, down 4%.
- Gross margin rose to 78% from 72%; the company now expects full-year 2026 gross margin of approximately 76%.
- Net loss was $10.1 million ($0.24 per share) versus $15.2 million ($0.38 per share) a year earlier; adjusted EBITDA loss was $5.1 million, down 39%.
- Full-year 2026 revenue outlook of $90 million to $92 million was unchanged; total operating expense outlook is $109 million to $111 million.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.